A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results

A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results

Background: Approximately 70% of patients with metastatic breast cancer (MBC) develop bone metastases. Despite advances in systemic treatment options and the use of bone targeted agents in the management of bone metastases to reduce skeletal morbidity, there remains an unmet need for further treatme...

Full description

Bibliographic Details
Main Authors: Brown, J. (Author), Brown, S.R (Author), Coleman, R. (Author), Eastell, R. (Author), Gath, J. (Author), Howell, S. (Author), Kendall, J. (Author), MacPherson, I. (Author), Murden, G. (Author), Palmieri, C. (Author), Purohit, K. (Author), Rathbone, E. (Author), Taylor, C. (Author), Twelves, C. (Author), Wilson, C. (Author), Winter, M. (Author)
Format: Article
Language:English
Published: Elsevier GmbH 2022
Subjects:
Bone metastases
Bone turnover markers
Breast cancer
Capecitabine
Radium-223
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items